The library included a panel of 730 compounds of the NCI Clinical
Collection (NCC) [22 (link), 23 (link)] and 101 FDA-Approved Oncology
drug Set IV from NCI/DTP Open Chemical Repository (http://dtp.cancer.gov )
encompassing the agents that have been in phase I–III clinical trials
and are part of the NIH Roadmap Molecular Libraries Screening Centers Network
[49 (link)]. Controls and
several screening compounds were added to the plates manually (full list in
Table S1 ). PDAC
cells were plated in 96-well flat-bottom plates (Sarstedt, Numbrecht, Germany)
at 2500 cells per well 48 hours prior to adding the drugs. The compound library
was maintained as 10 mM stock in DMSO which has been used for further serial
dilution using robotic high throughput plate handling automation (CyBio, Jena,
Germany) to create 2 replicates of each library plate at 10 μM, 2
μM, 0.4 μM, 0.08 μM and 0.016 μM final drug
concentrations. Sensitivity was assessed on day 6 using standard viability assay
(CellTiter-Glo, CellTiter-Blue, Promega, Madison, WI, USA)[50 (link)].
Collection (NCC) [22 (link), 23 (link)] and 101 FDA-Approved Oncology
drug Set IV from NCI/DTP Open Chemical Repository (
encompassing the agents that have been in phase I–III clinical trials
and are part of the NIH Roadmap Molecular Libraries Screening Centers Network
[49 (link)]. Controls and
several screening compounds were added to the plates manually (full list in
cells were plated in 96-well flat-bottom plates (Sarstedt, Numbrecht, Germany)
at 2500 cells per well 48 hours prior to adding the drugs. The compound library
was maintained as 10 mM stock in DMSO which has been used for further serial
dilution using robotic high throughput plate handling automation (CyBio, Jena,
Germany) to create 2 replicates of each library plate at 10 μM, 2
μM, 0.4 μM, 0.08 μM and 0.016 μM final drug
concentrations. Sensitivity was assessed on day 6 using standard viability assay
(CellTiter-Glo, CellTiter-Blue, Promega, Madison, WI, USA)[50 (link)].
